Histone Deacetylase Inhibitors in Programmed Cell Death and Cancer Therapy
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Histone deacetylase (HDAC) inhibitors, such as suberoylanilide hydroxamic acid (SAHA), are targeted anticancer agents that have significant anticancer activity at doses well tolerated by patients. Recently, we found that HDAC inhibitors can trigger both mitochondria-mediated apoptosis and caspase-independent autophagic cell death, indicating potential benefit of HDAC inhibitors in treating cancers with apoptotic defects. We also found that thioredoxin (TRX) might play a significant role in HDAC inhibitor-induced cell death, and HDAC inhibitors increase TRX levels in normal cells but not transformed cells, which is likely to be one of the reasons why HDAC inhibitors preferentially kill cancer cells. In this review, we discuss the study of HDAC inhibitors in cell death and cancer research, the implications of our recent findings, and some outstanding questions that need to be addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Self-citation
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Self-citationHistone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 874
Alao, J. P. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-24 · Cited by 871
DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies
Lyko, F., & Brown, R. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji311 · Cited by 510
Microglia: Agents of the CNS Pro-Inflammatory Response
Rodríguez-Gómez, J. A., Kavanagh, E., Engskog-Vlachos, P., Engskog, M. K. R., Herrera, A. J., Espinosa-Oliva, A. M., Joseph, B., Hajji, N., Venero, J. L., & Burguillos, M. A. (2020) · Cells · doi:10.3390/cells9071717 · Cited by 365
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
Duvic, M., & Vu, J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1111 · Cited by 344
The Thioredoxin System as a Therapeutic Target in Human Health and Disease
Mahmood, D. F. D., Abderrazak, A., El Hadri, K., Simmet, T., & Rouis, M. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4757 · Cited by 305
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
Ropero, S., Fraga, M. F., Ballestar, E., Hamelin, R., Yamamoto, H., Boix-Chornet, M., Caballero, R., Alaminos, M., Setien, F., Paz, M. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1773 · Cited by 290
Hodawadekar, S. C., & Marmorstein, R. (2007) · Oncogene · doi:10.1038/sj.onc.1210619 · Cited by 272
Fotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., Bernards, R., & La Thangue, N. B. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.001 · Cited by 138
Fujii, K., Suzuki, N., Ikeda, K., Hamada, T., Yamamoto, T., Kondo, T., & Iwatsuki, K. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2011.11.010 · Cited by 10
Metadata
- Authors
- Marks, P. A., & Jiang, X.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2005-01-28
- Volume
- 4
- Issue
- 4
- Pages
- 549-551
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W2013715448
- Cited by
- 142
- References
- 1
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.